Close Menu

Alcon

Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Solid Cancers
Patent Number: 8,148,069
Filed: Jan. 3, 2007

Silence Therapeutics has scored a victory in its efforts to defend its intellectual property estate, announcing this week that the US Patent and Trademark Office has upheld the validity of four patents related to the design of RNAi molecules.

Title: Oncogenic ALL-1 Fusion Proteins for Targeting Drosha-Mediated microRNA Processing
Patent Number: 8,053,186
Filed: June 13, 2008
Inventor: Carlo Croce, Ohio State University

The patent, EP1633890, is part of the so-called Zamore IP estate and claims rules for designing RNAi molecules with improved potency and fewer off-target effects.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.